Insider Selling: Illumina (NASDAQ:ILMN) Director Sells $91,617,385.80 in Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 457,858 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the sale, the director owned 2,372,694 shares of the company’s stock, valued at $474,776,069.40. This represents a 16.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Illumina Trading Down 3.1%

NASDAQ:ILMN traded down $6.15 on Thursday, reaching $193.72. The company’s stock had a trading volume of 4,268,800 shares, compared to its average volume of 1,934,392. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $207.00. The stock has a 50 day moving average price of $179.92 and a 200 day moving average price of $148.41. The firm has a market cap of $29.25 billion, a price-to-earnings ratio of 36.14, a price-to-earnings-growth ratio of 2.86 and a beta of 1.45. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period last year, the company earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Illumina

A number of hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp acquired a new stake in Illumina during the 2nd quarter worth approximately $293,846,000. Focus Partners Advisor Solutions LLC purchased a new stake in shares of Illumina during the second quarter worth $2,628,000. State of Wyoming purchased a new stake in shares of Illumina during the second quarter worth $262,000. S&CO Inc. acquired a new stake in shares of Illumina in the second quarter valued at $3,164,000. Finally, GSA Capital Partners LLP purchased a new position in Illumina in the second quarter valued at $261,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective for the company in a research report on Thursday, May 14th. Leerink Partners boosted their target price on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. Sanford C. Bernstein restated a “market perform” rating and set a $215.00 price target on shares of Illumina in a research note on Friday, July 31st. Canaccord Genuity Group raised their price target on Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research report on Monday. Finally, Citigroup lifted their price objective on Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $188.40.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.